These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21548719)

  • 1. Pegaptanib octasodium for the treatment of diabetic macular edema.
    Schartman JP; Coney JM; Hornik JH; Miller DG
    Expert Opin Pharmacother; 2011 Jun; 12(8):1317-1323. PubMed ID: 21548719
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
    Morjaria R; Chong NV
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1185-92. PubMed ID: 24856361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema.
    Giuliari GP; Guel DA; Gonzalez VH
    Curr Diabetes Rev; 2009 Feb; 5(1):33-8. PubMed ID: 19199896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
    Adamis AP; Altaweel M; Bressler NM; Cunningham ET; Davis MD; Goldbaum M; Gonzales C; Guyer DR; Barrett K; Patel M;
    Ophthalmology; 2006 Jan; 113(1):23-8. PubMed ID: 16343627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 7. [Molecular targeting therapy for diabetic retinopathy].
    Nakao S; Yoshida S; Enaida H; Ishibashi T
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():628-46. PubMed ID: 23513915
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anti-VEGF therapy to treat diabetic macular edema].
    Takamura Y
    Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
    Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
    Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
    Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD;
    Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegaptanib for branch retinal vein occlusion.
    Wong I; Koo S; Chan C
    Am J Ophthalmol; 2010 Jul; 150(1):129; author reply 129-30. PubMed ID: 20609713
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of pegaptanib (Macugen(®) ) injection on retinal and retrobulbar blood flow in retinal Ischaemic diseases.
    Hussain RM; Harris A; Siesky B; Yung CW; Ehrlich R; Prall R
    Acta Ophthalmol; 2015 Aug; 93(5):e399-e400. PubMed ID: 25639282
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medications for diabetic macular edema].
    Kitano S
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():275-9. PubMed ID: 15999719
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema.
    Querques G; Bux AV; Iaculli C; Noci ND
    Int Ophthalmol; 2011 Dec; 31(6):525-7. PubMed ID: 22203375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema.
    Querques G; Bux AV; Martinelli D; Iaculli C; Noci ND
    Acta Ophthalmol; 2009 Sep; 87(6):623-30. PubMed ID: 19678810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
    Salam A; DaCosta J; Sivaprasad S
    Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic Retinopathy and Diabetic Macular Edema.
    Cohen SR; Gardner TW
    Dev Ophthalmol; 2016; 55():137-46. PubMed ID: 26501152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.